ALDX Aldeyra Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1341235 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY55.7%
TTM EPS YoY57.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.3%
ROA-31.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.8%
Debt / equity0.00x
Current ratio5.45x
Interest coverage-21.39x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.84M | $3.48M | $2.41M | $4.30M | $5.43M | $8.51M | $7.42M | $14.63M |
| SG&A expense | $2.30M | $2.37M | $1.14M | $2.36M | $2.57M | $1.66M | $3.00M | $1.95M |
| Operating income | -$4.14M | -$5.85M | -$3.55M | -$6.67M | -$8.00M | -$10.17M | -$10.43M | -$16.58M |
| Interest expense | $438 | $23 | $468,678 | $475,259 | $475,903 | $470,618 | $483,529 | $470,863 |
| Net income | -$3.76M | -$5.45M | -$3.45M | -$6.46M | -$7.69M | -$9.77M | -$9.93M | -$15.81M |
| EBITDA | -$3.98M | -$5.78M | -$3.48M | -$6.60M | -$7.94M | -$10.11M | -$10.37M | -$16.51M |
| EPS (basic) | -0.06 | -0.09 | -0.06 | — | -0.13 | -0.16 | -0.17 | — |
| EPS (diluted) | -0.06 | -0.09 | -0.06 | — | -0.13 | -0.16 | -0.17 | — |
| Weighted avg. shares (diluted) | 60.35M | 60.32M | 60.32M | — | 60.13M | 60.05M | 59.89M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $40.97M | $45.09M | $65.00M | $70.04M | $59.34M | $41.24M | $50.35M | $54.53M |
| Short-term investments | — | — | — | $0 | $15.96M | $40.68M | $39.71M | $46.62M |
| Current assets | $42.92M | $47.38M | $66.27M | $71.78M | $77.46M | $84.56M | $92.73M | $104.07M |
| PP&E, net | $17,991 | $20,544 | — | $0 | — | — | — | $0 |
| Total assets | $43.38M | $47.54M | $66.48M | $72.06M | $77.80M | $84.96M | $93.20M | $104.61M |
| Current liabilities | $7.88M | $9.66M | $24.33M | $27.81M | $28.48M | $29.53M | $14.29M | $18.60M |
| Short-term debt | $0 | $0 | $15.30M | $15.25M | $15.20M | $15.15M | $0 | $31,372 |
| Long-term debt | — | — | $0 | $0 | $0 | $0 | $15.10M | $15.00M |
| Total debt | — | — | $15.30M | $15.25M | $15.20M | $15.15M | $15.10M | $15.03M |
| Total liabilities | $8.16M | $9.66M | $24.33M | $27.81M | $28.56M | $29.67M | $29.60M | $33.60M |
| Shareholders' equity | $35.22M | $37.89M | $42.16M | $44.25M | $49.24M | $55.29M | $63.60M | $71.00M |
| Net debt | — | — | -$49.70M | -$54.79M | -$44.14M | -$26.09M | -$35.25M | -$39.50M |
| Shares outstanding | 60.36M | 60.32M | 60.32M | 60.16M | 60.16M | 60.05M | 60.05M | 59.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.12M | -$4.59M | -$5.11M | -$5.30M | -$7.02M | -$8.56M | -$12.47M | -$12.04M |
| Investing cash flow | $0 | -$23,097 | $0 | $16.00M | $25.00M | -$554,126 | $7.29M | -$1.56M |
| Financing cash flow | $9,692 | -$15.30M | $71,140 | $0 | $120,746 | $0 | $1.00M | $7,779 |
| Depreciation & amortization | $154,712 | $70,706 | $66,599 | $65,116 | $63,683 | $62,282 | $60,912 | $64,373 |
| Stock-based compensation | $1.11M | $1.64M | -$987,554 | $1.09M | $2.58M | $196,564 | $2.22M | $1.26M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.